Top Page
Renalytix
(OTC:RENX)
Renalytix (RENX) vs. S&P 500 (SPY)
Renalytix Business Overview & Revenue Model
Renalytix Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 2.35M | 2.29M | 3.40M | 2.97M | 1.49M | 0.00 | Gross Profit |
| 299.00K | 156.00K | 701.00K | 918.00K | 687.00K | -74.00K | EBIT |
| -24.09M | -29.61M | -42.35M | -57.37M | -32.61M | -11.08M | EBITDA |
| -23.79M | -28.52M | -41.71M | -52.69M | -33.69M | -11.08M | Net Income Common Stockholders |
| -28.03M | -33.46M | -45.61M | -45.28M | -34.73M | -9.84M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 17.83M | 4.68M | 26.14M | 44.08M | 74.45M | 14.28M | Total Assets |
| 19.93M | 7.97M | 42.12M | 63.26M | 102.58M | 41.30M | Total Debt |
| 0.00 | 8.54M | 12.15M | 12.71M | 352.00K | 622.00K | Net Debt |
| -9.87M | 3.85M | -12.53M | -28.63M | -64.81M | -12.67M | Total Liabilities |
| 1.30M | 15.83M | 23.66M | 20.09M | 7.48M | 5.34M | Stockholders Equity |
| 18.62M | -7.85M | 18.45M | 43.17M | 95.10M | 35.96M |
| Cash Flow | Free Cash Flow | ||||
| -19.58M | -30.11M | -32.67M | -46.44M | -26.26M | -11.37M | Operating Cash Flow |
| -24.44M | -30.11M | -32.67M | -45.74M | -24.63M | -10.06M | Investing Cash Flow |
| 17.00K | -4.00K | 0.00 | -694.00K | -741.00K | -485.00K | Financing Cash Flow |
| 11.32M | 10.25M | 15.12M | 25.52M | 77.24M | 16.54M |
Renalytix Technical Analysis
Renalytix Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | £105.62M | 214.51 | 0.72% | 0.69% | -1.22% | -92.99% | |
52 Neutral | £14.47M | ― | -2.49% | ― | -3.76% | 65.81% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
44 Neutral | £54.22M | ― | 9.99% | ― | ― | 70.92% | |
37 Underperform | £29.81M | ― | 425.97% | ― | -22.16% | 50.89% |
Renalytix Earnings Call Summary
Renalytix Corporate Events
Renalytix announced it will release its unaudited interim results for the six months ending December 31, 2024, on March 18, 2025. The company is hosting both online and in-person investor presentations to discuss these results, inviting current shareholders and interested investors to participate. The announcement underscores the company’s commitment to transparency and engagement with stakeholders, as well as its strategic focus on expanding the deployment of kidneyintelX.dkd across the U.S. healthcare system.
Renalytix PLC has announced a significant change in its shareholder structure, with UBS Group AG’s trading book holdings in the company falling below the 5% threshold. This change means that UBS’s holdings in Renalytix are now exempt from reporting obligations, indicating a potential shift in the investment landscape for the company.
Renalytix announced that its kidneyintelX.dkd test has been featured in the Journal of the American Society of Nephrology, highlighting its significance in precision medicine for diabetic kidney disease. The test’s inclusion in the KDIGO guidelines and its role in facilitating personalized care underscores its potential to transform treatment paradigms, especially with new drug approvals like Ozempic for DKD, by providing risk-based treatment pathways that enhance patient outcomes while controlling healthcare costs.
Renalytix PLC announced a significant change in its shareholder structure as UBS Group AG, through its Investment Bank & Global Wealth Management, has reduced its holdings in the company to below 5%. This reduction in UBS’s trading book holdings means they are now exempt from reporting their stake in Renalytix PLC, highlighting a notable shift in investor interests and potential impacts on the company’s market perception.
Renalytix has provided a trading update indicating that it remains on track to meet its financial targets for the fiscal years 2025 and 2026, supported by a significant increase in the number of tests ordered and a successful £11.8m funding round. The company expects to report revenues of $1.3 million for the first half of fiscal year 2025, with continued growth driven by new partnerships and increased sales representative productivity. The expansion includes onboarding a large New York-based primary care network, which has bolstered growth and is expected to encourage further adoption of kidneyintelX.dkd in the coming year.
Renalytix plc has announced the granting and cancellation of options for its executives and directors to align its share option scheme with current market conditions. This move is meant to incentivize and retain key personnel by adjusting option targets to better reflect the company’s performance and market position, thus ensuring alignment with shareholder interests.
Renalytix announced that its Chief Technology Officer and Executive Director, Fergus Fleming, has purchased 25,000 shares in the company, demonstrating confidence in its operations and market positioning. This transaction highlights the company’s ongoing commitment to addressing the significant challenge of chronic kidney disease, with its kidneyintelX.dkd tool already showing a substantial impact in improving diagnosis and treatment rates.
Renalytix plc announced that all resolutions were passed at its Annual General Meeting. This includes the reappointment of auditors and authorization of share issuance under the equity incentive plan. The successful passage of these resolutions supports the company’s operational strategies and continues its commitment to advance kidney disease management through its FDA-approved test, kidneyintelX.dkd, which is gaining traction in the U.S. healthcare market.
Renalytix plc announced updates during its AGM, highlighting the success of a recent £11.8m funding round and a strategic refocus aimed at delivering scalable revenues with a reduced cost base. The company emphasizes its FDA-approved, Medicare-reimbursed kidneyintelX.dkd test, which is recommended in international clinical guidelines and now available to approximately 14 million US diabetic kidney disease patients. The firm is leveraging an integrated sales approach with electronic health record systems to increase test adoption and efficiency. Renalytix aims to reduce cash burn by mid-2025 and expects to achieve a $3.2m revenue target for the year ending in June 2025, aligning management and shareholder interests through incentive plans.